The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy
 Response in Hormone Receptor Positive Breast Cancers
The clinical trial will be a prospective, two strata, non-blinded, single institution, Health
 Canada approved, Window of Opportunity trial with 2 weeks of pre-surgical endocrine therapy
 using either anastrozole or tamoxifen. Tissue from the initial biopsy and from surgery will
 be sent for Ki67 analysis using the NanoString® Assay.
Inclusion Criteria:

 -  Any patient with histologically confirmed newly diagnosed operable ER+, Her2 negative
 invasive carcinoma on diagnostic core biopsy that has a radiographic size ≥ 1.5 cm

 -  Histology has to be ductal, lobular or mixed

 -  Surgery date planned in the next 2-6 weeks

 -  Negative pregnancy test if of child baring potential

 -  Post-menopausal status verified by FSH and Estradiol (with 6 months of amenorrhea)

 Exclusion Criteria:

 -  Previous treatment with endocrine therapy, chemotherapy or chest wall radiation within
 last 6 months

 -  Known metastatic or recurrent breast cancer.